Oncology Diagnostics
Receive regular headline summaries whenever high-quality news is generated for Oncology Diagnostics. We'll never share your email address with others.
| Shares Healthcare News With (link): | |
|---|---|
| Healthcare Topics | Cancer Therapy, Genomics, Precision Oncology, Infectious Disease, Clinical Diagnostics, Molecular Diagnostics, Digital Health, Personal Genome Diagnostics, Medical Research |
| Companies | Biocept, Thermo Fisher, Merck |
| Capital Firms | Zacks Investment Research, Maxim Group |
Selected Headlines
| Date | Headline (link) | Source | Relevant Snippet |
|---|---|---|---|
| 5/16/2021 | Immunoscore is now available in Rectal Cancer for expert | Globe Newswire | Immunoscore® is now available in Rectal Cancer for expert clinical centers through an Innovation Access Program May 11, 2021 08:00 ET HalioDx Marseille, FRANCE Immunoscore® heads up to become the standard precision tool for the “Watch and Wait” strategy in locally advanced rectal cancer Expert clinical centers already involved worldwide in this new Innovation Access Program Marseille, France, May 11, 2021 - HalioDx SAS, the immuno-oncology diagnostics ... |
| 5/15/2021 | Exact Sciences' First-Quarter Results Show Its Strength Under Pressure | fool.com | ... still able to post 10% year-over-year quarterly sales growth for Cologuard.IMAGE SOURCE: GETTY IMAGES.Precision oncology fell short It's unlikely that the $16.8 billion market-cap company's late 2019 purchase of oncology diagnostics player Genomic Health has been as fruitful as management hoped it would be. Exact Sciences' sales in precision oncology for the quarter came in at $129 million, a measly 1% increase from year-ago ... |
| 5/15/2021 | Exact Sciences' First-Quarter Results Show Its Strength Under Pressure | newsbreak.com | ... headwinds, the company was still able to post 10% year-over-year quarterly sales growth for Cologuard.Precision oncology fell short It's unlikely that the $16.8 billion market-cap company's late 2019 purchase of oncology diagnostics player Genomic Health has been as fruitful as management hoped it would be. Exact Sciences' sales in precision oncology for the quarter came in at $129 million, a measly 1% increase from year-ago ... |
| 4/27/2021 | Geneseeq and AstraZeneca Collaborate to Build Guangzhou Bio-Diagnostics Innovation Center | PR Newswire | TORONTO , April 27, 2021 /PRNewswire/ - Geneseeq Technology Inc. ("Geneseeq"), a precision oncology diagnostics company, and AstraZeneca (LSE: AZN) (STO: AZN) (Nasdaq: AZN ), a global biopharmaceutical company, are excited to announce their strategic collaboration to establish a Bio-Diagnostic Innovation Center in Guangzhou, China . The center is expected to initiate an integrative and patient-centric program where disease diagnosis, treatment, and rehabilitation coexist. The center will combine Geneseeq's expertise in developing ... |